Business
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update, including highlights of positive initial data from the ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that is relapsed, refractor
About this update from Enliven Therapeutics, Inc.
[{"type":"text","content":"Reported positive initial Phase 1b data for ELVN-001 in CML ","length":59,"tagName":"p","attribs":{}},{"type":"text","content":"Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026","length":96,"tagName":"p","attribs":{}},{"type":"text","content":"Key data readout, regulatory interactions, and operational catalysts throughout 2026","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029","length":160,"tagName":"p","attribs":{}},{"type":"text","content":"BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update, including highlights of positive initial data from the ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors (TKIs) (NCT05304377).","length":628,"tagName":"p"},{"type":"text","content":""2025 was a year of meaningful progress as we advanced ELVN-001 toward a Phase 3 pivotal clinical trial," said Rick Fair, Chief Executive Officer of Enliven. "As we move into 2026, we're entering one of the most active and transformative periods in Enliven's history – with an important data readout, key regulatory interactions, and the planned initiation of our ENABLE-2 pivotal trial. We are focused on execution to demonstrate ELVN-001's potential as a best-in-class ATP-competitive inhibitor for people living with CML."","length":557,"tagName":"p"},{"type":"text","content":"ELVN-001 Program Highlights ","length":27,"tagName":"p"},{"type":"text","content":"ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with CML.","length":199,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Company announced pos...